Clinical trials: Ewings Sarcoma
Soft Tissue Sarcoma, Bone Sarcoma
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
The purpose of this study is to determine whether nivolumab plus ipilimumab are effective and safe in the treatment of sarcoma and endometrial carcinoma patients with somatic deficient MMR as a selection tool.
- Conditions
- Soft Tissue Sarcoma, Bone Sarcoma, Chondrosarcoma, Gastrointestinal Stromal Sarcoma
- Trial name
- NCT02982486
- Testing
- Ipilimumab, Nivolumab
- Volunteers
- 60 people
- Sponsor
- Assaf-Harofeh Medical Center
Lymphoma, Neuroblastoma
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
RATIONALE: New imaging procedures, such as whole-body MRI, may improve the ability to detect metastatic cancer and determine the extent of disease.
- Conditions
- Lymphoma, Neuroblastoma, Sarcoma
- Trial name
- NCT00072488
- Testing
- computed tomography, magnetic resonance imaging, positron emission tomography
- Where
- 21 sites in United States, Canada
- Volunteers
- 226 people
- Sponsor
- American College of Radiology Imaging Network
Sarcoma, Osteoid Sarcoma
Combination Immunotherapy Targeting Sarcomas
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged.
- Conditions
- Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
- Trial name
- NCT04433221
- Testing
- Multiple sarcoma-specific CAR-T cells and sarcoma vaccines
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Sarcoma
Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives
RATIONALE: Studying samples of blood in the laboratory from patients with cancer and their relatives may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- GENEWING (NCT01210209)
- Testing
- genome-wide association study
- Where
- France
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Institut Curie
Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
This phase II trial is studying how well oxaliplatin works in treating young patients with recurrent solid tumors that have not responded to previous treatment.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor, Childhood Hepatoblastoma, Childhood Hepatocellular Carcinoma
- Trial name
- NCT00091182
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Pediatric Renal Tumor, Metastatic Osteosarcoma
Indo-cyanine Green (ICG) in Paediatric Oncology MIS
Indo-cyanine green (ICG) is a dye that has been used for a variety of adult and paediatric uses since 1956. Over the past few years, near infrared (NIRF) technology has been developed which allow is use as a fluorescence agent…
- Conditions
- Pediatric Renal Tumor, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma, Pulmonary Metastasis
- Trial name
- NCT04854018
- Testing
- Indocyanine green
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Birmingham Women's and Children's NHS Foundation Trust
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.